Abstract
Aryl trifluoromethyl ethers (OCF3), aryl difluoromethyl ethers (OCHF2), and aromatic sulfur pentafluorides (SF5) are of particular interest in drug design due to their favorable properties including high chemical and metabolic stability, suitable lipophilicity, unique electronic properties, definitive conformational characteristics, and their roles in molecular recognition in binding sites of biological targets. The deployments of these functional groups are relatively rare, although these compounds are increasingly found in pharmaceutical agents. This chapter describes a number of FDA-approved drugs and drug candidates that contain OCF3, OCHF2, and SF5 groups: Riluzole for amyotrophic lateral sclerosis Delamanid and Pretomanid for tuberculosis, Pantoprazole for erosive esophagitis, Roflumilast for chronic obstructive pulmonary disease ELQ-300 and DSM-265 for malaria, BMS-665053 for depression, and a fluoro-analog of Rimonabant for obesity. The successful case studies substantiate the prominence of their utilities and synthetic enablement in drug discovery research.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
